Medical treatment of deep venous thrombosis;MEDIKAMENTOSE THERAPIE DER TIEFEN VENENTHROMBOSE

Therapeutische Umschau

Volumn 53, Issue 4, 1996, Pages 272-276

  Bounameaux, H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION; CHEMICALLY INDUCED DISORDER; LEG; PARTIAL THROMBOPLASTIN TIME; RECURRENT DISEASE; REVIEW; THROMBOPHLEBITIS; VASCULARIZATION;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LEG; PARTIAL THROMBOPLASTIN TIME; RECURRENCE; THROMBOPHLEBITIS;

EID: 0029917309     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bounameaux H., Bongard O., Huber O.: Epidemiologie und Risikofaktoren der venösen Thromboembolie. Ther. Umschau 49, 799, 1992.
2. National Institutes of Health Consensus Development Conference: Thrombolytic therapy in thrombosis: a NIH development conference. Ann. Intern. Med. 93, 141, 1980.
3. Goldhaber S. Z., Buring J. E., Lipnick R. J., Hennekens C. H.: Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am. J. Med. 76, 393, 1984.
4. Eichlisberger R., Frauchiger B., Widmer M. T., Widmer L. K., Jäger K.: Spätfolgen der tiefen Venenthrombose: ein 13-Jahres Follow-up von 223 Patienten. Vasa 23, 234, 1994.
5. Sidorov J.: Streptokinase vs heparin for deep venous thrombosis. Can lytic therapy be justified? Arch. Intern. med. 149, 1841, 1989.
6. O'Meara J. J., McNutt R. A., Evans A. T., Moore S. W., Downs S. M.: A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis N. Engl. J. Med. 330, 1864, 1994.
7. Brandjes D. P. E., Heijboer H., Büller H. R., de Rijk M., Jagt H., ten Cate J. W.: Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N. Engl. J. Med. 327, 1485, 1992.
8. Hommes D. W., Bura A., Mazzolai L., Büller H. R., ten Cate J. W.: Subcutaneous heparin compared with continuous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann. Intern. Med. 116, 279, 1992.
9. Bounameaux H., Goldhaber S. Z.: Uses of low-molecular-weight heparin. Blood Rev. 9, 213, 1995.
10. Levine M., Gent M., Hirsh J. [for the Canadian Treatment study Group]: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal ddep-vein thrombosis. N. Engl. J. Med. 334, 677, 1896.
11. Koopman M. M. W., Pradoni P., Piovella F. [on behalf of the TASMAN Study Group]: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334, 682, 1996.
12. Warkentin T., Levine M. N., Hirsh J., Horsewood P., Roberts R. S., Gent M., Kelton J. G.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330, 1995.
13. Leizorovicz A., Simonneau G., Decousus H., Boissel J. P.: Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 309, 299, 1994.
14. Hyers T. N., Hull R. D., Weg J. G.: Antithrombotic therapy for venous thromboembolic disease. Chest 102 (Suppl.), 408S, 1992.
15. Sarasin F. P., Bounameaux H.: Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb. Haemost. 71, 286, 1994.
16. Landefeld C. S., Goldman L.: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87, 144, 1989.